Equities analysts predict that Axsome Therapeutics Inc (NASDAQ:AXSM) will report earnings of ($0.41) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Axsome Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.39). Axsome Therapeutics reported earnings per share of ($0.31) during the same quarter last year, which suggests a negative year over year growth rate of 32.3%. The firm is expected to announce its next earnings results on Friday, November 8th.
On average, analysts expect that Axsome Therapeutics will report full-year earnings of ($1.40) per share for the current fiscal year, with EPS estimates ranging from ($1.54) to ($1.17). For the next year, analysts anticipate that the firm will report earnings of ($1.30) per share, with EPS estimates ranging from ($1.72) to ($0.85). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10).
A number of research firms recently commented on AXSM. HC Wainwright set a $30.00 price target on Axsome Therapeutics and gave the stock a “buy” rating in a research report on Monday, June 24th. Zacks Investment Research raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 target price (up previously from $25.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 28th. BidaskClub lowered shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 12th. Finally, ValuEngine lowered shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Axsome Therapeutics has an average rating of “Buy” and a consensus price target of $30.83.
In other news, Director Mark E. Saad bought 3,500 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was acquired at an average cost of $22.33 per share, with a total value of $78,155.00. Following the completion of the acquisition, the director now owns 7,002 shares of the company’s stock, valued at $156,354.66. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Nick Pizzie bought 1,920 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was purchased at an average cost of $20.80 per share, with a total value of $39,936.00. Following the completion of the acquisition, the chief financial officer now directly owns 1,920 shares of the company’s stock, valued at approximately $39,936. The disclosure for this purchase can be found here. Insiders have purchased 5,820 shares of company stock worth $127,391 in the last three months. 27.50% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $52,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $72,000. Schroder Investment Management Group purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $76,000. Focused Wealth Management Inc purchased a new position in shares of Axsome Therapeutics during the first quarter valued at approximately $64,000. Finally, SG Americas Securities LLC purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $167,000. 45.10% of the stock is owned by hedge funds and other institutional investors.
Axsome Therapeutics stock traded up $2.23 during trading hours on Tuesday, hitting $27.64. The stock had a trading volume of 852,320 shares, compared to its average volume of 1,690,860. The company’s 50-day simple moving average is $25.89. The company has a debt-to-equity ratio of 1.08, a quick ratio of 5.68 and a current ratio of 5.68. The stock has a market cap of $874.61 million, a P/E ratio of -24.03 and a beta of 2.64. Axsome Therapeutics has a fifty-two week low of $1.94 and a fifty-two week high of $28.70.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Featured Story: How does equity income fit into an investing strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.